Evogliptin tartrate|1222102-51-3|(DA-1229 tartrate)-陌孚医药/Medlife

您当前的位置：

Evogliptin tartrate (Synonyms: DA-1229 tartrate)

目录号: PL13890 纯度: ≥99%

CAS No. :1222102-51-3

商品编号	规格	价格	会员价
PL13890-5mg	5mg	¥4327.27	请登录
PL13890-10mg	10mg	¥7170.91	请登录
PL13890-25mg	25mg	¥13600.00	请登录
PL13890-50mg	50mg	¥21018.18	请登录
PL13890-100mg	100mg	¥30909.09	请登录
PL13890-200mg	200mg	询价	询价
PL13890-500mg	500mg	询价	询价
PL13890-10mM*1mLinDMSO	10mM*1mLinDMSO	¥4760.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	Evogliptin tartrate
英文名称	Evogliptin tartrate
英文别名	Evogliptin (tartrate);R14RT6A3LK;Evogliptin Tartrate;Evogliptin tartrate [WHO-DD];2-Piperazinone, 4-((3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl)-3-((1,1-dimethylethoxy)methyl)-, (3R)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1);DA-1229 tartrate;Evogliptin tartrate
Cas No.	1222102-51-3
分子式	C₂₃H₃₂F₃N₃O₉
分子量	551.51
包装储存	4°C, sealed storage, away from moistur In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

产品详情

Evogliptin (DA-1229) tartrat 是一种口服有效的 DPP4 抑制剂，在小鼠模型中具有显著而持久的降糖效果。Evogliptin tartrat 还可通过诱导自噬来抑制肝细胞的炎症和纤维化信号的产生。Evogliptin tartrat 可用于 2 型糖尿病、骨质疏松症，肾功能损害以及慢性肝脏炎症的研究。

生物活性

Evogliptin (DA-1229) tartrate is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin tartrate also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin tartrate can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation.

性状

Solid

IC50 & Target[1][2]

DPP-4

体外研究(In Vitro)

Evogliptin tartrate (2.49 mM; 12 h) efficiently inhibits mDPP4 (membrane DPP4) enzymatic activity in PWM-induced H9 Th1 cells.
Evogliptin tartrate prevents inflammatory and fibrotic signaling through autophagy induction in primary hepatocytes of ATG7-Cre mice. has not independently confirmed the accuracy of these methods. They are for reference only.Cell Viability Assay

体内研究(In Vivo)

Evogliptin tartrate (100, 300 mg/kg; in animal feedings; single daily for 10 weeks) exhibits antidiabetic effects on HFD/STZ mice and improves glucose intolerance and insulin resistance. has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model:

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moistur In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

ClinicalTrial

参考文献

[1]. Yoon H, et al. Effects of the Antidiabetic Drugs Evogliptin and Sitagliptin on the Immune Function of CD26/DPP4 in Th1 Cells. Biomol Ther (Seoul). 2021 Mar 1;29(2):154-165.
[2]. Seo H Y, et al. Evogliptin Directly Inhibits Inflammatory and Fibrotic Signaling in Isolated Liver Cells. International Journal of Molecular Sciences, 2022, 23(19): 11636.

溶解度数据	In Vitro: DMSO : 100 mg/mL (181.32 mM; Need ultrasonic)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation